Tilray Inc. ($TLRY) Stock Forecast: Down 5.3% Today

What is Tilray Inc.?

Tilray Brands Inc. (TLRY) is a key player in the cannabis industry, with a focus on medical and recreational products in the US market. The stock recently faced significant downward movement.

Why is Tilray Inc. going down?

TLRY stock is down 5.3% on Apr 28, 2026 19:55

• The exclusive launch of Manitoba Harvest's Superfood Smoothie Boosters at Sprouts Farmers Market suggests potential competition in the health and wellness sector, impacting investor sentiment towards Tilray.
• Concerns about growing competition and market saturation in the US cannabis market may have prompted a sell-off of TLRY shares.
• Anticipation surrounding Tilray's upcoming Q3 earnings report, which showed a wider loss than expected but beat revenue estimates, created uncertainty among investors despite the company's market outperformance.
• The market's mixed reactions to Tilray's Q3 earnings, with the stock price dropping despite surpassing revenue expectations, may have led investors to reassess the company's financial standing and future outlook.

TLRY Price Chart

TLRY Technical Analysis

TLRY News

Manitoba Harvest Launches Superfood Smoothie Boosters, Exclusively at Sprouts Farmers Market Nationwide

Manitoba Harvest has launched new Superfood Smoothie Boosters exclusively at Sprouts Farmers Market. These boosters, available in "Glowing Greens" and "Radiant Reds" flavors, offer a convenient way to add plant-based protein, fiber, and herbal ingredients to smoothies. Crafted with Regenerative Organic Certified® hemp and nutrient-dense powders, the products are designed to support overall health and wellness.

https://investingnews.com/manitoba-harvest-launches-superfood-smoothie-boosters-exclusively-at-sprouts-farmers-market-nationwide/

US Cannabis Market Report Analysis Report 2026-2034 Featuring Canopy Growth, Tilray Brands, Curaleaf, Aurora Cannabis, Jazz Pharma, GTI, Trulieve, Cresco Labs, Organigram Global, TerrAscend

The US cannabis market is projected to grow significantly from USD 11.73 billion in 2025 to USD 40.41 billion by 2034, driven by increasing state-level legalization, growing acceptance for medical and recreational use, and innovations in product categories. Despite challenges such as regulatory fragmentation and illicit market competition, the industry is expanding rapidly with major players and states like California and New York leading the growth. The report highlights increased consumer accessibility, scientific acceptance, and product diversification, including edibles, beverages, and cannabinoid-based wellness items.

https://uk.finance.yahoo.com/news/us-cannabis-market-report-analysis-150700142.html

Tilray Brands Inc. stock rises Monday, outperforms market

Tilray Brands Inc. (TLRY) stock rose 2.07% on Monday, closing at $6.89. This performance outpaced the broader market, as the NASDAQ Composite Index increased by 0.20% while the Dow Jones Industrial Average fell by 0.13%. The rise broke a two-day losing streak for Tilray.

https://www.marketwatch.com/data-news/tilray-brands-inc-stock-rises-monday-outperforms-market-4c29c790-6dbd32ff9105

Tilray Brands' Q3 earnings on the horizon: What's in the offing?

This article announces that Tilray Brands' Q3 earnings report is approaching. It indicates that investors and analysts are keenly awaiting the report to understand the company's financial performance and future outlook. The article likely discusses potential areas of focus in the earnings announcement.

https://www.msn.com/en-us/money/topstocks/tilray-brands-q3-earnings-on-the-horizon-what-s-in-the-offing/ar-AA1ZQFn0?ocid=finance-verthp-feeds&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-c

Tilray Brands, Inc. (TLRY) reports Q3 loss, beats revenue estimates

Tilray Brands, Inc. (TLRY) reported a wider-than-expected loss in its fiscal third quarter but surpassed revenue estimates. The company posted a loss of $0.12 per share, which was $0.06 worse than analyst predictions, while revenue reached $195 million, exceeding expectations by $12.3 million. Despite the revenue beat, the stock experienced a slight dip after the announcement.

https://www.msn.com/en-us/money/topstocks/tilray-brands-inc-tlry-reports-q3-loss-beats-revenue-estimates/ar-AA1ZUPNC?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1&bundles=feat-es2020-c

Trending Today

Dogecoin ($DOGE) Crypto Forecast: Up 5.1% Today

Wheat ($WHEAT) Commodity Forecast: Up 5.2% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.3% Today

Incyte Corporation ($INCY) Stock Forecast: Up 1.3% Today

Applied Materials Inc. ($AMAT) Stock Forecast: Down 5.0% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 7.3% Today

United Parcel Service Inc. ($UPS) Stock Forecast: Down 4.9% Today

ON Semiconductor Corporation ($ON) Stock Forecast: Down 5.2% Today

Alcoa Corporation ($AA) Stock Forecast: Down 5.1% Today

Universal Health Services Inc. ($UHS) Stock Forecast: Down 6.9% Today

Tilray Inc. Price History

02.03.2026 - TLRY Stock was up 6.5%

• Strong Q3 earnings and a surge in international cannabis revenue contributed to Tilray exceeding revenue expectations, prompting a positive market response.
• Analysts raised their rating on Tilray to Buy, setting a price target of $10, and expressed optimism about the company's future growth potential.
• Despite the favorable earnings, concerns over varying margin trends, uncertainty in EPS reporting, and analyst downgrades caused a brief 5.1% decrease in the stock price after the earnings release, revealing the difficulties in maintaining consistent profitability amid revenue growth.

02.03.2026 - TLRY Stock was up 5.4%

• Despite achieving record Q3 revenue of $206.7 million, Tilray's stock declined by 5.1% due to concerns about mixed margin trends, confusion around EPS reporting, and analyst downgrades.
• The company's efforts in international cannabis revenue growth and strategic acquisitions were somewhat overshadowed by difficulties in converting top-line growth into consistent profit enhancements.
• Investors have reservations concerning a notable adjusted EPS shortfall, ongoing shareholder dilution, and slow advancements in U.S. cannabis rescheduling, which have influenced market perceptions despite the positive revenue outcome.
• Tilray's stock performance fell short of market expectations, closing well below its 52-week high, reflecting investor sentiment towards the company's financial performance and growth strategies.

27.03.2026 - TLRY Stock was down 5.3%

• Investors opted to take profits today amidst Tilray's stock decline, following a period of volatility and speculation.
• Concerns arose among investors due to a director's sale of over 33,000 company shares, potentially impacting outlook and causing fears of dilution.
• Although positive developments such as U.S. cannabis rescheduling and the company's expansion plans emerged, the stock's decline suggests some skepticism among investors regarding the recent surge.
• Tilray's larger-than-expected quarterly loss and negative net margins may have also influenced the stock's downturn, prompting an evaluation of the company's financial standing in light of sector trends.

07.03.2026 - TLRY Stock was down 5.1%

• Despite a positive day in the broader market, Tilray's stock faced a downward trend, closing at $6.66.
• Analysts hold differing views on Tilray, resulting in a consensus "Hold" rating and an average price target of $11.20. This reflects uncertainty regarding the company's future profitability.
• Investors have expressed concerns about Tilray's persistent operational losses, narrow margins, and high expenses, leading to a substantial 97% decline in the stock value over the past five years.
• The recent uptick in Tilray's stock price is possibly linked to short-term positive momentum driven by operational advancements in Q3. However, technical analysis indicates a consolidation range between $6.50 and $7.00, with potential downside risks due to the absence of strong buy signals.

01.03.2026 - TLRY Stock was down 5.1%

• Despite reporting record Q3 revenue of $206.7 million, Tilray's stock experienced a bearish movement due to concerns over a significant adjusted EPS miss, continuous shareholder dilution, and slow progress in U.S. cannabis rescheduling.
• The surge in international cannabis sales by 73% sparked a rally in Tilray's shares, but the narrowed net loss that still missed consensus might have contributed to the overall bearish sentiment.
• Anticipation of strong Q3 earnings, a new product launch, and decreased short interest led to a premarket surge in Tilray's stock, indicating short-term gains amidst a longer-term downtrend.
• Investors are eagerly waiting for revenue growth to translate into sustainable profitability for Tilray, as the company navigates through challenges and opportunities in the cannabis market.

22.03.2026 - TLRY Stock was up 14.6%

• The surge in Tilray Brands Inc. (TLRY) can be linked to the filing of additional legal exhibits related to a registration statement. This move likely boosted investor confidence in the company's adherence to regulations and transparency.
• Despite the notification of an insider selling 232,872 shares, the market appeared more interested in the registration of 398,666 resalable common shares, issued for acquiring the Lyphe Group. This development hinted at potential growth avenues for the company.
• The stock's positive trajectory might also reflect a recovery from the previous day's downturn, where it performed below the market average. Investors seem to perceive this as a favorable moment to purchase following the recent price dip.
• In summary, the optimistic market sentiment surrounding Tilray Brands Inc. could stem from its regulatory compliance, growth potential from acquisitions, and a rebound from the previous day's underperformance.

28.03.2026 - TLRY Stock was down 5.3%

• The exclusive launch of Manitoba Harvest's Superfood Smoothie Boosters at Sprouts Farmers Market suggests potential competition in the health and wellness sector, impacting investor sentiment towards Tilray.
• Concerns about growing competition and market saturation in the US cannabis market may have prompted a sell-off of TLRY shares.
• Anticipation surrounding Tilray's upcoming Q3 earnings report, which showed a wider loss than expected but beat revenue estimates, created uncertainty among investors despite the company's market outperformance.
• The market's mixed reactions to Tilray's Q3 earnings, with the stock price dropping despite surpassing revenue expectations, may have led investors to reassess the company's financial standing and future outlook.

23.03.2026 - TLRY Stock was up 8.6%

• Tilray's stock price rose by more than 30% due to discussions about the possible reclassification of cannabis, which could support the company's plans for growth in the US market.
• There is excitement among investors regarding the potential regulatory changes that could lead to tax benefits and smoother operations for cannabis firms.
• Tilray's preparedness to tap into the US medical cannabis sector after a potential reclassification showcases strategic opportunities for growth and market expansion.
• By collaborating with BrewDog USA, Tilray is demonstrating a diverse approach to innovation and product offerings, which is contributing to its optimistic market sentiment and upward trajectory.

24.03.2026 - TLRY Stock was down 12.9%

• The stock price of Tilray Brands plummeted by 11.8% following insider selling of over 33,000 shares by a director, leading to increased trading volume and negative investor sentiment.
• Despite optimism in the cannabis sector due to potential reclassification of cannabis to Schedule III, concerns about potential dilution, wider-than-expected quarterly losses, and negative net margins contributed to the bearish movement.
• While there was speculation and anticipation surrounding the Trump administration's possible rescheduling of cannabis, the lack of official confirmation led to uncertainty and a sell-off in Tilray's stock.
• Tilray's readiness to expand into the U.S. medical cannabis market post-rescheduling highlights the company's strategic positioning, but until concrete regulatory changes are announced, the stock may continue to face volatility and downward pressure.

21.03.2026 - TLRY Stock was down 5.2%

• TLRY experienced a strong bearish movement today despite recent positive news and stock price gains in the past few days.
• The stock's poor performance could be attributed to the challenges faced in the legal marijuana market, including restrictive regulations on branding and advertising, intense competition, and uncertainty surrounding potential U.S. legalization.
• Despite reaffirming its leadership in medical cannabis and positive company news, the stock's reaction indicates a stock-specific response rather than a broader sector trend.
• The bearish movement today may be a result of profit-taking by investors following the recent price increases, as well as concerns about the company's ability to overcome regulatory hurdles and achieve sustained profitability in a competitive market.

14.03.2026 - TLRY Stock was up 8.5%

• The stock had a strong bullish movement today, closing 4.5% higher at $6.75.
• This positive momentum could be attributed to the recent launch of PORTAL™, a new high-intensity cannabis brand targeting experienced consumers in Canada, filling a market gap and potentially driving investor optimism.
• Despite facing legal challenges, such as the $11.3 million lawsuit from the Bob Marley estate over licensing royalties, Tilray's strategic product offerings and market expansion efforts seem to have resonated positively with investors, leading to today's bullish market movement.

13.03.2026 - TLRY Stock was up 5.2%

• Despite recent declines in the stock price and mixed trading sessions, today's bullish movement suggests a potential shift in investor sentiment.
• The launch of PORTAL™, a new high-intensity cannabis brand targeting experienced consumers, could have positively impacted the stock price as it signals the company's efforts to expand its product offerings and cater to specific market segments.
• The ongoing legal battle with the Bob Marley estate over licensing royalties might have initially caused uncertainty among investors, leading to the recent declines. However, the bullish movement today could indicate that investors are optimistic about a potential resolution or are focusing more on the company's product innovations.
• It's essential for investors to closely monitor any updates regarding the legal dispute and the company's financial performance to make informed decisions about their investments in Tilray Brands Inc.